Liver-Specific Expression Cassettes for Hemophilia Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for hemophilia A and B face challenges in achieving therapeutic levels of coagulation factors VIII and IX due to limitations in vector capacity, immunogenicity, and efficiency, particularly in liver-directed gene therapy, where high doses are required and immune responses pose risks.
Innovation Solution
Development of nucleic acid expression cassettes and vectors incorporating specific regulatory elements such as the Serpin enhancer and transthyretin promoter, combined with codon-optimized transgenes, to enhance liver-specific expression of FIX and FVIII, achieving synergistic increases in expression levels and reducing vector doses needed for therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high vector doses are used to achieve therapeutic levels of coagulation factors, then expression levels improve, but immune responses and safety risks worsen
Solution Approach 1:
The patent changes the parameters of the expression cassette by incorporating specific regulatory elements (Serpin enhancer, transthyretin promoter) and codon-optimized transgenes. This optimization allows achieving therapeutic expression levels at lower vector doses, thereby reducing immune responses and safety risks while maintaining productivity.
Solution Approach 2:
The patent creates a composite expression cassette structure combining multiple regulatory elements (Serpin enhancer, transthyretin promoter, polyadenylation signals) with codon-optimized transgenes. This composite design synergistically enhances liver-specific expression efficiency, allowing lower dosing and reduced immunogenicity while maintaining high factor production.
2Quantity of substance
If vector capacity is limited, then smaller expression cassettes are used, but expression efficiency and therapeutic levels worsen
Solution Approach 1:
The patent optimizes the parameters of the expression cassette by using compact but highly efficient regulatory elements. The Serpin enhancer and transthyretin promoter provide high expression efficiency in a space-efficient design, allowing maximum therapeutic output within the limited vector capacity of AAV and other viral vectors.
Solution Approach 2:
The patent extracts and uses only the essential core regulatory elements needed for high-level liver-specific expression. By focusing on the most critical components (Serpin enhancer, transthyretin promoter) and removing non-essential sequences, the design achieves high expression efficiency within strict size constraints.
3Productivity
If liver-specific expression is enhanced, then therapeutic efficacy improves, but complexity of regulatory elements increases
Solution Approach 1:
The patent changes the parameters of regulatory elements by selecting specific combinations that provide optimal liver-specificity and expression strength. The Serpin enhancer combined with transthyretin promoter creates a balanced system achieving high therapeutic efficacy without excessive complexity, as these elements are well-characterized and can be precisely engineered.
Data Source
AI summary
The present invention relates to nucleic acid expression cassettes and vectors containing liver-specific regulatory elements and codon-optimized factor IX or factor VIII transgenes, methods employing these expression cassettes and vectors and uses thereof. The present invention is particularly useful for applications using liver-directed gene therapy, in particular for the treatment of hemophilia A and B.